{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-008282","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.908470+00:00","generated_at":"2026-05-26T04:15:04.850397+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"AIM ImmunoTech appoints David Chemerow as independent director; reduces stockholder meeting quorum to 33 1/3%","bullets":["David Chemerow appointed as independent director, effective February 24, 2025.","Chemerow brings 40+ years of finance, accounting, and operations leadership experience; former CFO of Comscore.","Bylaws amended to reduce quorum for stockholder meetings from 40% to 33 1/3%.","Chemerow will be compensated same as other directors; serves until 2025 Annual Meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-008282","json":"https://secwatch.observer/filing/0001493152-25-008282.json","markdown":"https://secwatch.observer/filing/0001493152-25-008282.md","text":"https://secwatch.observer/filing/0001493152-25-008282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315225008282/0001493152-25-008282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315225008282/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:15:04.850397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38e51e0242","claim":"David I. Chemerow was appointed as Director at AIM ImmunoTech Inc..","evidence_excerpt":"On February 26, 2025, AIM ImmunoTech Inc. (the \"Company\") issued a press release announcing the appointment of David I. Chemerow to its Board of Directors (the \"Board\"), effective February 24, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315225008282/0001493152-25-008282-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"08a496438cf9416aac93d33395ee73803f28fe10","claim":"AIM ImmunoTech Inc.: Reduced quorum for stockholder meetings from 40% to 33 1/3% (effective 2025-02-24).","evidence_excerpt":"On February 24, 2025, the Company adopted Restated and Amended Bylaws. The Restated and Amended Bylaws revise Section 1.6 Quorum, reducing the quorum for stockholder meetings from 40% to 33 and 1/3%.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315225008282/0001493152-25-008282-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-02-24"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}